The ubiquity of the contamination was striking. Three compounds in particular, trimethoprim, chlortetracycline, and sulfamethoxazole, were detected in 100 percent of the samples analyzed, meaning that no single site in the entire river system was free of antibiotic residues. Concentrations of individual antibiotics ranged widely, from as little as 2.8 nanograms per liter for lomefloxacin to a maximum of 1235.8 nanograms per liter for erythromycin, a macrolide antibiotic commonly used in both human medicine and livestock production. While such concentrations are measured in parts per trillion and are far below therapeutic doses, chronic exposure at these levels is precisely the condition that scientists worry can drive the evolution and spread of antibiotic resistance genes in aquatic microbial communities.

Spatial patterns in the data told a clear story about how the pollution moves through the watershed. Antibiotic concentrations followed the order of midstream greater than downstream greater than upstream, suggesting that the middle reaches of the river system, where urban development and population density are highest, act as a major loading zone. Equally telling was the comparison between the main river channel and its tributaries: levels in the tributaries were generally higher than in the mainstream, indicating that the main stem of the Beiyun River is strongly influenced by inflows from the smaller streams draining its sub-catchments. In effect, the tributaries function as conveyor belts, collecting antibiotic residues from neighborhoods, hospitals, livestock facilities, and industrial sites, and delivering them into the larger river.

To move beyond simple detection and identify where the antibiotics actually come from, the research team employed a quantitative source-apportionment method known as principal component analysis with multiple linear regression, or PCA-MLR. This technique, originally developed for tracing air pollution sources, works by reducing a large dataset of measured pollutant concentrations into a small number of underlying statistical factors, each of which corresponds to a characteristic pollution signature. Regression analysis then estimates how much each factor contributes to the observed concentrations of individual compounds. In this study, the model resolved the antibiotic load in the Beiyun River system into six identifiable pollution sources plus one unknown source, providing a quantitative breakdown that single-source monitoring cannot achieve.

The results of the apportionment pointed to two dominant contributors. Mixed pollution source inputs, a category that aggregates diffuse urban runoff, agricultural activity, and other combined pathways, explained 35.4 percent of the variance in the data, making it the single largest source. Wastewater treatment plant discharges ranked a close second, accounting for 31.1 percent of the variance. The chemical fingerprints of these two sources were distinct. The mixed source contributed most heavily to the quinolone antibiotics difloxacin and ciprofloxacin, accounting for 72.1 percent and 71.4 percent of their respective loads. The wastewater treatment plant source, by contrast, dominated the sulfonamide class, contributing 74.8 percent of sulfacetamide, 73.9 percent of sulfachloropyridazine, 73.3 percent of sulfadimethoxine, and 70.9 percent of sulfadiazine.

The prominence of wastewater treatment plants as a source is a recurring theme in urban water pollution research, and the Beiyun findings add Beijing to a long list of cities where conventional treatment infrastructure falls short of removing pharmaceutical micropollutants. Standard activated-sludge treatment processes are designed to strip out organic matter, nitrogen, and phosphorus, but many antibiotics are either poorly biodegraded or are re-released back into the water column as parent compounds or metabolites during sludge handling. Sulfonamides in particular are known to pass through treatment barriers with relatively high efficiency, which is consistent with the strong association between these compounds and treatment plant discharges found in the new study. Upgrading plants with advanced oxidation processes, ozonation, or activated carbon polishing has been shown elsewhere to substantially reduce pharmaceutical loads, and the source apportionment here suggests such upgrades would deliver measurable benefits in this watershed.

On the question of ecological risk, the study’s multi-level assessment delivered a nuanced verdict. Overall, the ecological risks posed by antibiotics across the Beiyun River system remained at acceptable levels, a conclusion that may surprise readers given the universal detection of the compounds. Risk quotients, calculated by comparing measured environmental concentrations with predicted no-effect concentrations for sensitive aquatic species, stayed within thresholds regarded as tolerable for the system as a whole. However, the assessment flagged specific exceptions. Tetracyclines showed relatively high risk quotients, reflecting the combination of their persistent detection and the known sensitivity of algae and other primary producers to this drug class. Clarithromycin, a macrolide, exhibited low but non-negligible risks to certain aquatic species, consistent with prior toxicological work showing that macrolides can affect photosynthesis and growth in freshwater organisms at environmentally relevant concentrations.

The significance of these findings extends well beyond the boundaries of a single watershed. Antibiotic residues in surface water are widely recognized as a key driver of antimicrobial resistance, one of the most serious public health threats of the coming decades. When bacteria in rivers are exposed to sub-inhibitory concentrations of antibiotics over long periods, strains carrying resistance genes gain a selective advantage, and those genes can then move between species and environments through horizontal gene transfer. Urban rivers like the Beiyun, which flow through neighborhoods where millions of people live, work, and recreate, represent critical nodes in this process, linking clinical and agricultural antibiotic use to the broader environmental resistome. Understanding exactly which sources contribute which compounds is therefore a prerequisite for designing effective interventions.

The study also highlights the value of source apportionment as a policy tool. Knowing that mixed diffuse inputs and treatment plant effluents together account for roughly two-thirds of the antibiotic burden allows regulators to prioritize interventions, whether through upgrading treatment technology, controlling runoff from livestock and aquaculture operations, tightening prescription and disposal practices, or managing the hydrological connections between tributaries and the main stem. The finding that tributaries consistently carry higher concentrations than the mainstream suggests that targeted action on sub-catchment scale pollution could yield disproportionate benefits for the entire river system.

For Beijing, a megacity of more than twenty million people whose rivers have undergone decades of engineering and restoration, the new data provide a baseline against which future management efforts can be measured. The research was funded by the Natural Science Foundation of Jiangxi Province, the Jiangxi Provincial Department of Science and Technology, and the National Natural Science Foundation of China, and was conducted by a team led from Jiangxi Agricultural University together with collaborators in Beijing. As antibiotic use continues to grow worldwide and urbanization intensifies across Asia, Africa, and Latin America, the Beiyun River system offers a case study in what complete pharmaceutical contamination of an urban watershed looks like, and a demonstration that with careful chemical detective work, the sources of that contamination can be named, ranked, and ultimately addressed.

Subject of Research: Antibiotic contamination, sources, and ecological risks in an urbanized Beijing watershed

Article Title: Occurrence, source apportionment, and risk assessment of antibiotics in the Beiyun River system: a highly urbanized watershed in Beijing, China

Article References: Lou, Q., Zhao, X., Zhang, X., Liang, L., Han, L., Tu, W., & Chen, M. (2026). Occurrence, source apportionment, and risk assessment of antibiotics in the Beiyun River system: a highly urbanized watershed in Beijing, China. Environmental Monitoring and Assessment, 198(10), Article 1125. https://doi.org/10.1007/s10661-026-15933-7

Image Credits: AI Generated

DOI: 10.1007/s10661-026-15933-7

Keywords: antibiotics, Beiyun River, Beijing, water pollution, source apportionment, PCA-MLR, ecological risk, wastewater treatment, sulfonamides, tetracyclines, macrolides, quinolones

The stakes could hardly be higher. Brain tumors remain among the most lethal malignancies in medicine, characterized by dismal prognoses and stubborn resistance to conventional therapies, while neuroblastoma—a cancer of the sympathetic nervous system that strikes mainly in early childhood—poses its own formidable treatment challenges. Patients undergoing intensive chemotherapy for these diseases are profoundly immunosuppressed, and bacterial infections during treatment are common, feared, and frequently fatal. Antibiotic prophylaxis and empiric treatment are therefore standard practice, not optional extras. Clinical studies have documented significant rates of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma, and febrile neutropenia in solid tumor patients is routinely managed with broad-spectrum cephalosporins like cefazolin’s relatives. If those protective drugs simultaneously erode the efficacy of the anticancer regimen, the trade-off at the bedside becomes far more complicated than anyone assumed.

The Turkish team, led by İlayda Şişli together with Melek Yüce and Esra Albayrak, set out to probe precisely this dual role. Their question was deceptively simple: what happens to cancer cells when a widely used antibiotic and a chemotherapy drug share the same culture medium? Cefazolin, marketed in some countries as Cefamezin, is a beta-lactam antibiotic that works by disrupting bacterial cell wall synthesis—utterly irrelevant machinery for human cells, which have no cell walls. Yet a accumulating literature suggests cephalosporins are not pharmacologically inert toward tumor cells. Some studies have reported that certain cephalosporins can suppress cancer growth, for example by triggering ferroptosis, an iron-dependent form of cell death, in nasopharyngeal carcinoma cells, or by targeting Aurora B kinase in lung cancer models. Others have found the opposite: ceftazidime and cefepime were shown to antagonize the effect of 5-fluorouracil in colon cancer cells. The picture is inconsistent, drug-specific, and cell-type-specific—which is exactly why direct experimental testing matters.

To interrogate the interaction, the researchers used two complementary experimental readouts. The first was the MTT assay, a colorimetric test in which metabolically active cells convert a yellow tetrazolium compound into a purple formazan product; the amount of purple dye serves as a proxy for the number of viable, metabolically competent cells. The second was flow cytometry, a technique that fires cells one by one through a laser and quantifies their DNA content and fluorescent markers, allowing researchers to determine what fraction of the cell population sits in each phase of the cell cycle—G0/G1, S, G2/M—and what fraction has fallen into the sub-G0/G1 debris characteristic of dying cells. Together, these methods capture both the net effect on cell survival and the mechanistic fingerprint of how the drugs act on the cell division machinery.

The results were clear on both fronts. Irinotecan, a topoisomerase I inhibitor that works by trapping the enzyme responsible for relieving torsional stress in DNA during replication, thereby converting an essential enzyme into a DNA-damaging poison, induced significant cytotoxicity in both LN-18 glioblastoma and SH-SY5Y neuroblastoma cells. Flow cytometry showed the expected signature: an increase in the sub-G0/G1 fraction, indicating cells with fragmented DNA heading toward death, alongside arrest in the S phase, where DNA replication stalls, and the G2/M phase, where cells with damaged DNA halt before mitosis. This is textbook topoisomerase poison behavior—the drug prevents cells from copying and dividing their genome cleanly, and the damaged cells accumulate and die.

Then came the twist. When cefazolin was added alongside irinotecan, the chemotherapy’s grip on the cells loosened. In the SH-SY5Y neuroblastoma cells, co-treatment with the antibiotic attenuated both the cytotoxicity and the cell cycle disruption that irinotecan alone had produced; the drug’s ability to push cells into the lethal sub-G0/G1 compartment and to arrest them in S and G2/M was measurably blunted. In the LN-18 glioblastoma cells, the pattern was similar but not identical: cefazolin partially weakened irinotecan’s inhibition of cell viability, while necrosis rates—death by a messier, non-programmed route—were not significantly altered. In both cell lines, the direction of the interaction was the same, and it was the wrong direction for a cancer patient: the antibiotic softened the chemotherapy’s blow.

What might explain this antagonism at the molecular level? The study does not pin down a mechanism, but the authors and the surrounding literature point to several plausible candidates. Antibiotics and chemotherapeutics can compete for cellular transport systems, altering how much drug actually reaches its intracellular target—a phenomenon first documented more than fifty years ago, when researchers showed that certain antibiotics interfered with the cellular transport and antitumor activity of methotrexate in leukemia cells. Antibiotics can also modulate drug efflux pumps such as BCRP/ABCG2, the molecular bouncers that expel chemotherapy agents from cells; indeed, one antibiotic, novobiocin, is famous precisely because it reverses such resistance. More speculatively, cefazolin could be altering mitochondrial function, reactive oxygen species generation, or the metabolic state of the tumor cells in ways that buffer them against topoisomerase-induced stress. Disentangling these possibilities will require the kind of mechanistic follow-up this in vitro study deliberately leaves open.

The broader context makes the finding more than a laboratory curiosity. A substantial clinical literature has already linked antibiotic exposure to worse cancer outcomes, most prominently with immune checkpoint inhibitors, where antibiotic use around the time of treatment has been associated with reduced clinical activity in advanced renal cell and non-small-cell lung cancer—largely attributed to disruption of the gut microbiome. A retrospective cohort study in glioblastoma patients has examined whether antibiotic drug use affects outcome and therapy-related toxicity, and reviews have framed antibiotics as a double-edged sword in oncology: indispensable against infection, potentially harmful against the tumor. Drug–drug interactions in cancer patients treated with oral anticancer agents are common and often overlooked, and fatal adverse drug events remain a sobering reminder that polypharmacy in oncology is a minefield. The new study extends this concern from the microbiome and the immune system down to the level of direct pharmacological interference between a cephalosporin and a topoisomerase inhibitor inside the tumor cell itself.

The researchers are careful about what their data can and cannot say. This was an in vitro study: two immortalized cell lines, culture dishes, and defined drug concentrations. Real glioblastomas and neuroblastomas live behind the blood–brain barrier, embedded in a microenvironment that no monolayer culture reproduces, and the concentrations and timing of cefazolin exposure in a treated patient differ from those in a flask. The authors explicitly note that their findings suggest cefazolin may antagonize the cytotoxic effects of irinotecan in vitro and underscore the need for further validation in in vivo and clinically relevant models. Animal studies and, ultimately, carefully designed clinical pharmacology studies would be needed before anyone could say whether a patient receiving cefazolin during irinotecan-based therapy actually experiences a meaningful reduction in tumor control. It is also worth remembering that irinotecan is not a mainstay of standard glioblastoma care, so the immediate clinical implications for current treatment protocols are limited; the finding speaks more to the principle than to a specific prescription today.

Even so, the message lands with force. Antibiotics are among the most frequently co-administered drugs in oncology, handed out for prophylaxis, for fever during neutropenia, and for intercurrent infections across every tumor type and every age group, from children with neuroblastoma to adults with glioblastoma. If a drug as ordinary as cefazolin can measurably weaken a chemotherapy agent in the dish, then the possibility deserves systematic scrutiny rather than assumption of safety. The study, funded by the Ondokuz Mayıs University Scientific Research Project Office and conducted with cell lines provided by Yeditepe University in Istanbul, is a small piece of evidence—but it points at a large blind spot. As cancer therapy grows ever more complex, the drugs given to protect patients from infection must be evaluated as potential players in the treatment itself, not as pharmacological bystanders. The next experiments, in animal models and eventually in patients, will determine whether this laboratory warning becomes a clinical rule.

Subject of Research: Interaction between the antibiotic cefazolin and the chemotherapeutic drug irinotecan in glioblastoma and neuroblastoma cells

Article Title: Antibiotic-chemotherapy interaction in brain tumors: cefazolin reduces chemotherapeutic efficacy of irinotecan in glioblastoma and neuroblastoma cells

Article References: Şişli, İ., Yüce, M., & Albayrak, E. (2026). Antibiotic-chemotherapy interaction in brain tumors: cefazolin reduces chemotherapeutic efficacy of irinotecan in glioblastoma and neuroblastoma cells. Medical Oncology, 43(11), Article 302. https://doi.org/10.1007/s12032-026-03403-6

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03403-6

Keywords: cefazolin, irinotecan, glioblastoma, neuroblastoma, antibiotics, chemotherapy, drug interactions, cell cycle, flow cytometry, MTT assay, topoisomerase inhibitor, cancer pharmacology

Oxazolidinones occupy a special place in modern medicinal chemistry. The five-membered ring, containing both a nitrogen and an oxygen atom adjacent to a carbonyl, appears in approved antibiotics and in countless molecules moving through drug discovery pipelines. Of particular urgency are the 5-(S)-aminomethyl oxazolidinones, scaffolds central to next-generation antibiotics designed to combat multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis, the pathogen behind one of the deadliest infectious diseases on Earth. As resistance spreads, the demand for efficient ways to assemble these rings has grown correspondingly sharper.

The trouble, historically, has been chirality. Molecules like oxazolidinones are three-dimensional objects, and their biological activity depends exquisitely on the handedness of their stereocentres. Conventional synthetic routes have leaned on the so-called chiral pool strategy, in which enantiopure amino alcohols harvested from natural sources serve as the key starting intermediates. That approach works, but it constrains chemists to the structural inventory of nature and demands lengthy sequences of functional group manipulations. Many methods exist to set the stereocentre at the 4-position of the ring, alpha to nitrogen, yet strategies for installing the 5-stereocentre, alpha to oxygen, have remained underdeveloped, leaving a stubborn gap in the synthetic toolbox.

The Caltech and Pittsburgh teams closed that gap with a two-stage reaction sequence performed by a single engineered enzyme. The cascade begins with aziridination, a transformation in which a nitrogen atom, delivered as a nitrene, is inserted across a carbon-carbon double bond to form a three-membered aziridine ring. The enzyme then guides a ring expansion of that strained intermediate, and the aziridine rearranges into the five-membered oxazolidinone. The result is a direct, enantioselective synthesis of clinically relevant and discovery-stage oxazolidinones starting from the simplest possible feedstocks: plain alkenes.

The choice of catalyst reflects a larger trend in synthetic biology. Haemproteins, enzymes built around an iron-containing porphyrin cofactor, have emerged in recent years as remarkably tunable platforms for carbene and nitrene transfer chemistry, reactions that no natural enzyme performs natively. Under the directed evolution methods pioneered in Arnold’s laboratory, researchers mutate and screen these proteins iteratively until the active site, originally shaped by evolution for tasks such as oxygen insertion, learn to conduct entirely new chemical transformations with high selectivity. In the new work, mutations introduced through directed evolution proved to be the decisive factor in controlling which mirror-image product the reaction delivers.

What makes the achievement stand out within the biocatalysis community is the class of alkene substrates involved. Until now, haemprotein-catalysed nitrene transfer has been largely restricted to conjugated systems such as styrenes, alkenes whose electronic character makes them reactive and easy to control. Unactivated alkenes, the saturated, electronically inert double bonds that pepper the structures of fats, terpenes, and countless pharmaceutical precursors, have resisted this chemistry. By extending nitrene transfer to these unactivated substrates, the new work substantially broadens the reach of enzymatic nitrene chemistry and opens a much wider swath of chemical space to biocatalytic functionalisation.

Behind the laboratory results lies a computational story. The team carried out detailed computational analysis of the reaction mechanism and found that the key mutations installed during directed evolution are directly responsible for the enantioselective formation of the products. In other words, the protein scaffold does not merely accelerate the reaction; specific amino acid substitutions sculpt the active site geometry so that the aziridination and ring expansion proceed with the precise three-dimensional outcome needed for the drug-like scaffold. This mechanistic understanding, developed jointly with Liu’s computational group at Pittsburgh, illustrates how theory and laboratory evolution now reinforce one another in modern enzyme design.

The practical implications are considerable. Because the cascade starts from simple alkenes and delivers enantioenriched oxazolidinones directly, it offers medicinal chemists a shorter, more modular path to analogues of clinically validated antibiotic scaffolds. Speeding access to structural variants matters enormously in anti-infective research, where teams must explore hundreds of derivative molecules to optimise potency, safety, and pharmacokinetics before a candidate can enter development. A route that removes the dependence on chiral-pool amino alcohols and sets the difficult 5-stereocentre in a single enzymatic operation could meaningfully compress discovery timelines for drugs aimed at resistant tuberculosis and beyond.

The study also adds a chapter to the broader narrative of enzyme engineering as a general-purpose tool for chemistry. Over the past two decades, the Arnold laboratory and others have shown that haemproteins can be reprogrammed to catalyse reactions absent from biology, including cyclopropanation, silicon-carbon bond formation, and a widening repertoire of nitrogen-transfer chemistry. Each extension of this platform challenges the traditional boundary between biological and abiological synthesis. The direct construction of oxazolidinone rings from unactivated alkenes now joins that list, and it does so with an added mechanistic account of how engineered mutations translate into stereochemical control.

For a field racing against the spread of antimicrobial resistance, the work carries both immediate and long-term significance. In the near term, the biocatalytic cascade provides a validated route to the exact scaffolds needed for the next generation of tuberculosis therapeutics. Over the longer term, the demonstration that engineered haemproteins can tame unactivated alkenes in enantioselective nitrene transfer suggests that many other transformations once considered the exclusive province of transition-metal catalysis may fall within reach of programmed biology. As the authors note, the chemistry was peer-reviewed and accepted by Nature, and while the published version is an early-release article subject to further editorial refinement, its conclusions are citable and carry a permanent digital identifier, marking a milestone that synthetic chemists and drug hunters alike will be watching closely.

Subject of Research: Biocatalytic enantioselective synthesis of chiral oxazolidinones from unactivated alkenes using engineered haemproteins

Article Title: Chiral oxazolidinones via biocatalytic aziridination of unactivated alkenes

Article References: Li, Z.-Q., Hanley, D., Zhang, Y., Xie, P.-P., Wu, S. J., Qin, Z.-Y., Zhang, C., Alfonzo, E., Li, F.-Z., Brinkman-Chen, S., Liu, P., & Arnold, F. H. (2026). Chiral oxazolidinones via biocatalytic aziridination of unactivated alkenes. Nature. https://doi.org/10.1038/s41586-026-11169-0

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11169-0

Keywords: biocatalysis, oxazolidinones, aziridination, nitrene transfer, directed evolution, haemproteins, antibiotics, tuberculosis, enantioselectivity, unactivated alkenes, enzyme engineering, drug discovery

The motivation behind the work lies in the arithmetic of the resistance crisis. In 2021, an estimated 4.71 million deaths worldwide were associated with bacterial antimicrobial resistance, including 1.14 million deaths directly attributable to it. Conventional antibiotics typically disable a single bacterial target, which means a single mutation can confer resistance. Newer strategies therefore seek agents that attack bacteria through several mechanisms at once, making it far harder for pathogens to survive. Antimicrobial peptides, the cationic membrane-attack molecules of the innate immune system, embody this philosophy, but their clinical use has been hampered by susceptibility to proteolysis, poor pharmacokinetics, and toxicity. Peptidomimetics, small molecules that mimic the architecture of these peptides, promise to retain their killing power while shedding their liabilities.

Clofoctol offered an unusually attractive starting point. Unlike generic hydrophobic scaffolds, it came with a documented history in humans: established pharmacokinetic behavior, pulmonary concentrations well above the levels needed to inhibit bacteria, and known effects on bacterial energy metabolism, including lowered intracellular ATP and disrupted membrane permeability. Its weaknesses were equally clear. It was essentially inactive against Gram-negative bacteria, poorly soluble in water, and potentially cytotoxic. Its precise molecular target had never been identified. Previous attempts to revive the drug had focused on reformulation and combination therapy, such as loading it into PLGA nanoparticles for lung delivery or pairing it with colistin against resistant Gram-negative pathogens. No one had yet redesigned the molecule itself.

The chemistry team, led by Jiayong Liu and colleagues, focused modifications on the phenolic hydroxyl group of clofoctol’s biphenyl scaffold, which defines the molecule’s hydrophobic domain. Through a modular synthetic route, they installed a library of cationic substituents, diethylamine groups, guanidinium groups, and chains of the amino acid arginine, connected by spacers of varying length. Each analogue was tested against a panel of Gram-positive and Gram-negative strains, including MRSA, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, with minimum inhibitory concentrations measured by standardized broth microdilution and hemolysis assessed against rabbit red blood cells.

The structure–activity relationships that emerged were instructive. Simple alkyl appendages abolished activity entirely, confirming that positive charge is essential for electrostatic engagement with negatively charged bacterial membranes. Spacer length proved critical: a four-carbon linker balanced potency and selectivity, while longer or shorter chains degraded one or both. Among the cationic groups, arginine emerged as the star. Tri-arginine substitution with a C-terminal methyl ester produced compound 30, which inhibited Gram-positive bacteria at just 0.39 micrograms per milliliter, a fourfold improvement over clofoctol on a weight basis, and brought E. coli activity from greater than 50 micrograms per milliliter down to 1.56. Its hemolytic activity was undetectable even at 200 micrograms per milliliter, yielding a selectivity index exceeding 512.

Compound 30 also tackled some of the most feared hospital pathogens. It retained potency against carbapenem-resistant Enterobacterales strains of E. coli and Klebsiella at concentrations of 1.56 to 3.125 micrograms per milliliter, conditions under which amoxicillin was essentially inert. Quantitative analysis of the SAR data reinforced a key design principle: calculated lipophilicity correlated negatively with both potency and selectivity, meaning that simply making the molecule greasier did not help. Success required a calibrated balance of charge and hydrophobicity, precisely the balance that tri-arginine esterification achieved. The modification also cured clofoctol’s solubility problem; compound 30 remained clear in water at 100 milligrams per milliliter, a concentration at which the parent drug was visibly insoluble even at one-tenth that level.

Time-kill experiments revealed remarkably fast bactericidal kinetics. At eight times the MIC, compound 30 completely eradicated both S. aureus and E. coli cultures within one hour, whereas vancomycin needed far longer and amoxicillin required a full day. Serial passage experiments underscored another advantage: over 21 transfers, the compound’s MIC never shifted, while norfloxacin resistance in S. aureus rose 256-fold by day 11 and amoxicillin resistance in E. coli climbed 16-fold by day 16. The compound also throttled biofilms, reducing S. aureus biofilm formation by more than 93 percent at twice the MIC and dismantling 83 percent of established E. coli biofilms at four times the MIC. Activity remained stable under physiological salt concentrations, a hurdle that defeats many cationic antimicrobials.

Mechanistic probing pointed to membrane disruption as the best-supported component of the compound’s action. SYTOX Green uptake, NPN permeability assays, and Live/Dead staining all showed concentration-dependent compromise of bacterial membrane integrity, and compound 30 displaced a fluorescent probe from lipopolysaccharide, the anchor of the Gram-negative outer membrane, by more than 80 percent at twice the MIC. Additional effects layered on top of this primary mechanism. In a purified-enzyme assay, compound 30 inhibited E. coli topoisomerase IV-mediated DNA decatenation by 96 percent at twice the MIC, and molecular docking into the ATP-binding pocket of the ParE subunit yielded a plausible binding pose at −10.2 kilocalories per mole, although the authors caution that intracellular target engagement has not yet been demonstrated. Treatment also depleted intracellular ATP and triggered reactive oxygen species accumulation; adding the ROS scavenger N-acetylcysteine raised the compound’s MIC four- to eightfold, supporting a functional contribution of oxidative stress to bacterial killing.

Transcriptome sequencing of E. coli after two hours of exposure identified 129 differentially expressed genes among 4,491 analyzed, with enrichment in the tricarboxylic acid cycle, methionine biosynthesis, and fatty acid catabolism, a pattern consistent with the observed energy and redox disturbances. The authors are careful to frame these as treatment-associated cellular responses rather than proof of direct targets, and the hierarchy among membrane damage, metabolic collapse, oxidative stress, and topoisomerase inhibition remains to be causally disentangled. What is clear is that the compound engages bacteria on multiple fronts, which plausibly explains both its rapid killing and its stubborn refusal to select for resistance under laboratory conditions.

The in vivo results, though early-stage, provide the most compelling evidence yet that the strategy can translate. In a murine keratitis model, topical 0.5 percent compound 30 reduced corneal S. aureus burden by 4.65 log units, statistically indistinguishable from 5 percent vancomycin, and cut P. aeruginosa burden by 3.81 log units, comparable to 0.3 percent gatifloxacin. Ocular safety testing with fluorescein staining showed no corneal epithelial damage even at three times the therapeutic dose. The authors emphasize that considerable work remains before clinical development: pharmacokinetics, corneal penetration, metabolic stability, long-term repeat-dose safety, broader panels of clinical isolates, and the precise causal mechanisms all require further study. Still, the study demonstrates a principle with wide implications. Rather than designing peptide mimics from scratch or hunting for entirely new scaffolds, medicinal chemists can take clinically validated drugs, install the cationic amphiphilic features that make antimicrobial peptides lethal, and produce candidates that are soluble, selective, fast-acting, and resistance-resistant. As the pipeline of conventional antibiotics continues to run dry, that recipe may prove one of the most practical paths forward.

Subject of Research: Development of clofoctol-derived cationic amphiphilic peptidomimetics as multi-mechanism broad-spectrum antibacterial agents

Article Title: Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms

Article References: Liu, J., Lin, J.-H., Wang, W., Li, H., Zheng, Y., Zhang, Y., Chen, M., Zhong, R., Xing, C., Dang, Y., Chang, H., Liu, S., & Lin, S. (2026). Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.007

Keywords: antimicrobial resistance, clofoctol, peptidomimetics, antibiotics, membrane disruption, MRSA, Gram-negative bacteria, biofilms, keratitis, drug discovery, topoisomerase IV, reactive oxygen species

The case centered on a pediatric patient with confirmed macrolide-resistant Mycoplasma pneumoniae infection who had been placed on oral doxycycline, a standard and generally well-tolerated choice for this pathogen. After five days of treatment, laboratory testing revealed something alarming: the child’s activated partial thromboplastin time, or APTT, had climbed to more than twice the normal value. The APTT is one of the two central screening tests of the coagulation system, measuring how long it takes blood to clot through the intrinsic pathway, the cascade of proteins that acts when blood encounters damaged vessel walls. A doubling of that time is not a subtle laboratory blip; it signals a substantial slowing of the clotting machinery and, in some patients, a genuine risk of abnormal bleeding.

What made the finding particularly puzzling, and clinically important, was its isolation. In many coagulation disorders, both major screening tests go awry together: the prothrombin time, or PT, which measures the extrinsic pathway, and the APTT, which measures the intrinsic pathway, rise in tandem. Isolated APTT prolongation, with a normal PT, points the diagnostic finger in a narrower set of directions, toward problems with specific factors such as factor VIII, IX, XI or XII, toward the presence of certain inhibitors, or, as the authors of this report explore at length, toward disruptions in the vitamin K–dependent clotting system. The rarity of isolated APTT prolongation as a drug reaction is precisely why this case caught the attention of the clinical team.

To establish whether doxycycline was genuinely responsible, the researchers turned to the World Health Organization’s standardized causality assessment framework for adverse drug reactions, a structured method that weighs timing, alternative explanations, prior reports, and the response to drug withdrawal. Their conclusion: doxycycline was a likely cause of the child’s coagulation dysfunction. That formal designation matters, because distinguishing a drug reaction from the many other things that can disturb clotting in a sick child, including the infection itself, requires disciplined causal reasoning rather than suspicion alone. The consequences were tangible, too. The coagulation abnormality extended the patient’s hospital stay, which under standard pharmacovigilance definitions classifies the event as a serious adverse drug reaction, not merely an incidental laboratory curiosity.

The heart of the paper, and its most thought-provoking section, is the authors’ exploration of how a tetracycline antibiotic might interfere with blood clotting in the first place. Their analysis focuses on the vitamin K cycle, the biochemical loop that keeps the clotting system supplied with functional proteins. In that cycle, vitamin K must be converted to its active reduced form, vitamin K hydroquinone, by the enzyme vitamin K epoxide reductase, known as VKOR. Vitamin K hydroquinone then serves as the essential cofactor for gamma-glutamyl carboxylase, or GGCX, the enzyme that chemically modifies the vitamin K–dependent clotting factors so they can bind calcium and assemble into a working clot. When the cycle runs smoothly, factors II, VII, IX and X are continuously carboxylated and ready; when it falters, non-functional precursors accumulate and clotting slows.

This is, notably, the same pathway targeted by warfarin, the classic anticoagulant, which works by inhibiting VKOR and starving the clotting factors of their vitamin K–dependent activation. The report’s authors use this well-mapped biochemistry as the framework for hypothesizing how doxycycline might produce an isolated APTT prolongation, examining the vitamin K epoxide, the hydroquinone intermediate, and the enzymatic steps that link them. While the exact mechanism remains to be fully established, the discussion represents an unusually detailed mechanistic exploration for a single case report, reflecting the team’s concern that a rare reaction may be hiding in plain sight within one of medicine’s most common prescriptions. Because only some patients exposed to the drug develop the abnormality, any plausible mechanism would need to account for that selectivity, whether through individual differences in vitamin K status, metabolism, or the interplay with concurrent infection.

The clinical team did not work in a vacuum. The paper is anchored by a comprehensive review of the existing literature on doxycycline and coagulation, which confirmed just how rarely such reactions have been reported despite the drug’s enormous global footprint. That scarcity is a double-edged sword for clinicians: it offers reassurance that the reaction is uncommon, but it also means that most practitioners will never have encountered it and may not think to check for it. The authors’ conclusion is measured but pointed. Doxycycline-related coagulation abnormalities may be rare in the literature, they write, but the potential risk should not be overlooked, and vigilance is warranted, particularly in patients who already have underlying coagulation disorders or who are receiving anticoagulant medications at the same time.

That vigilance, in practical terms, translates into a specific and inexpensive recommendation: monitoring the APTT for early detection of the abnormality. The activated partial thromboplastin time is a routine, rapidly performed laboratory test available in virtually every hospital, which makes surveillance for this particular reaction far more feasible than surveillance for many other rare drug toxicities. For a child on doxycycline for resistant Mycoplasma pneumoniae, a periodic APTT could catch a developing coagulation dysfunction before it produces symptoms, allowing the drug to be stopped or the patient observed before bleeding complications arise. The authors’ suggestion is especially relevant in regions where macrolide resistance has made doxycycline a frontline therapy for large numbers of children, multiplying the number of exposures and, statistically, the opportunities for rare reactions to surface.

The broader significance of the report lies in the tension it highlights between a drug’s reputation and its pharmacology. Doxycycline earned its reputation for safety through decades of use, and nothing in this single case overturns that standing. But rare adverse reactions are, by their nature, invisible to ordinary clinical experience and emerge only through careful documentation of individual cases, the kind of pharmacovigilance that this report exemplifies. The event occurred in a patient treated at institutions in Guangzhou, with the study approved by the ethics committee of The Third Affiliated Hospital of Guangzhou Medical University under approval number LW-2025-141, and with written informed consent for publication provided by the patient’s mother. The research team included Yiyang Li, Si Huang, Liman Li, Weihua Li, Jian Gu and Lichun Xie, with contributions spanning the Third Affiliated Hospital of Sun Yat-sen University, the Third Affiliated Hospital of Guangzhou Medical University, and Foshan Fosun Chancheng Hospital.

Published online on 24 September 2026 as an open-access article in BMC Pediatrics, the paper arrives at a moment when macrolide-resistant Mycoplasma pneumoniae is increasingly prevalent and doxycycline prescriptions are climbing in step. For the clinicians prescribing it, the message is not to abandon the drug, which remains a first-line and generally safe treatment, but to recognize that even familiar medications can surprise us. A prolonged APTT in a child on doxycycline, particularly when the prothrombin time remains normal, should now join the differential diagnosis as a possible drug reaction rather than being dismissed as a laboratory oddity. For researchers, the case opens a mechanistic question, the precise interaction between tetracyclines and the vitamin K–dependent carboxylation pathway, that a single report cannot fully answer. And for the pharmacovigilance community, it is a reminder that the safety profile of any drug is never finished being written, and that attentive clinicians documenting unusual cases remain one of the most important early-warning systems in medicine.

Subject of Research: Doxycycline-associated isolated APTT prolongation and the vitamin K mechanism in a pediatric patient

Article Title: Pediatric doxycycline-induced isolated APTT prolongation: a rare case with exploration of the vitamin K mechanism

Article References: Li, Y., Huang, S., Li, L., Li, W., Gu, J., & Xie, L. (2026). Pediatric doxycycline-induced isolated APTT prolongation: a rare case with exploration of the vitamin K mechanism. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07536-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07536-5

Keywords: doxycycline, coagulation dysfunction, APTT, vitamin K, macrolide-resistant Mycoplasma pneumoniae, adverse drug reaction, pediatrics, antibiotics, VKOR, gamma-glutamyl carboxylase, pharmacovigilance, case report

The research, conducted by Christopher J. Petty of the University of Georgia, Mindy Isaman and Linnea R. Freeman of Furman University, and colleagues at Furman and Clemson University, was published in the journal Biology of Sex Differences. The team set out to address two intertwined problems: the persistent excess of severe obesity among women compared with men, and the growing but still murky evidence that the gut microbiome shapes feeding behavior. Individuals with obesity are known to carry an altered gut microbiome, but whether those microbial differences actually drive overeating—or merely accompany it—has remained an open question, particularly with respect to sex differences.

To measure hedonic feeding with real precision, the researchers turned to an approach borrowed from economics rather than simple food-intake counts. Male and female Sprague-Dawley rats were trained in a de-escalating fixed ratio operant task built on behavioral economics principles. In this paradigm, animals work—pressing a lever—to earn high-fat, palatable reward pellets, and the price of those pellets, measured in effort, steadily increases. The design allows researchers to estimate two key parameters. The first is demand elasticity, denoted alpha, which captures how quickly an animal’s demand for the reward falls as the price of obtaining it rises. The second is demand at null cost, or Q0, an extrapolated prediction of how much the animal would consume if the reward required no effort at all. Together, these values describe not just how much an animal eats, but how much it values the food—an economic signature of hedonic drive.

The baseline results were clear and consistent with the team’s earlier work: female rats showed a significantly higher demand at null cost for the high-fat palatable pellets than male rats. In plain terms, when effort was stripped away, females valued and would consume more of the palatable reward than males. Because hedonic feeding is a well-recognized contributor to chronic overconsumption in environments saturated with calorie-dense foods, this kind of sex-linked difference in reward valuation is exactly the sort of biological signal that could help explain why severe obesity disproportionately affects women.

The next question was what might be driving that difference. Emerging evidence suggests the gut microbiome influences feeding behavior through several channels, including the production of short chain fatty acids, metabolites generated when gut bacteria ferment dietary fiber, and through effects on bile acids, molecules synthesized from cholesterol that aid fat digestion and also act as signaling agents in the gut and beyond. The researchers therefore administered an antibiotic cocktail in the rats’ drinking water to disrupt the gut microbiome, then re-ran the behavioral economics task to see whether wiping out the microbial community would change hedonic feeding in either sex.

The outcome was striking in its restraint. Female rats given antibiotics continued to show a higher demand at null cost compared with untreated male control rats, and—critically—the researchers found no statistically significant difference between antibiotic-treated males and females. In other words, disrupting the microbiome did not erase or meaningfully reshape the sex difference in hedonic reward valuation. The antibiotic treatment did do its biological job: when the team characterized the fecal microbiome at the genus level before and after antibiotic administration, they documented clear disruption to the bacterial community, alongside measured changes in fecal short chain fatty acid levels. They also profiled serum short chain fatty acid and bile acid levels at the end of the study, providing a metabolomic snapshot of the systemic consequences of microbial disruption.

What makes the finding conceptually important is what it rules out, or at least renders less likely as a simple explanation. If baseline differences in gut bacterial composition between males and females were the primary engine of the female rats’ stronger hedonic drive, collapsing that composition with antibiotics should have narrowed the gap. It did not. The authors also report that they did not observe striking baseline sex differences in fecal microbiome diversity and composition in the first place, which further weakens the notion that straightforward differences in which bacterial genera dominate the gut could account for the behavioral divergence. The study’s own conclusion is deliberately measured: these results bring into question whether the gut microbiome contributes to sex differences in hedonic feeding at all.

That said, the researchers are careful not to close the book on microbial influence. The gut microbiome is not a single variable but a network of interacting communities and metabolites, and antibiotics are a blunt instrument. The team points to network factors—such as the interplay between the microbiome and bile acids, which themselves show sex differences and can modulate feeding—as avenues requiring further investigation. Serum bile acid profiles measured at the study’s endpoint suggest that downstream signaling pathways, rather than raw bacterial composition, may be where sex-specific microbial effects on appetite ultimately reside, if they exist.

The work also carries a methodological lesson for the field. Behavioral economics approaches like the de-escalating fixed ratio task distinguish between consumption and motivation, two things that simple access-feeding experiments conflate. An animal that eats more of a tasty food at zero cost but gives up quickly when effort increases is economically different from one that persists at high prices, and only the second pattern reflects a genuine shift in reward valuation. By anchoring sex comparisons in demand curve parameters rather than grams consumed, studies of this kind can pinpoint whether the sexes differ in how much they value palatable food, in how sensitive they are to its cost, or both. In this case, the female-male difference lived specifically in the null-cost demand estimate.

For human health, the implications are cautious but meaningful. The finding that female rats place a higher intrinsic value on high-fat palatable food parallels epidemiological patterns in which women face higher rates of severe obesity, and it reinforces the idea that any intervention aimed at curbing pleasure-driven eating may need to account for sex as a fundamental biological variable rather than an afterthought. At the same time, the negative result on the microbiome tempers enthusiasm for microbial therapies—probiotics, targeted antibiotics, or fecal transplants—as quick fixes for hedonic overeating, at least until the relevant mechanisms are better mapped. Obesity, the authors note, remains a pressing public health issue, and hedonic feeding, while not its sole culprit, is one of its major contributing forces. Untangling which biological threads—hormonal, neural, microbial, or metabolic—woven together produce the sex difference in reward valuation will demand the kind of systematic, multi-dimensional profiling this study models: behavior, bacterial census, and metabolites measured in the same animals, before and after perturbation. The microbiome may yet play a role in appetite, but this careful experiment suggests that if it does, it operates through subtler, networked pathways than the simple presence or absence of particular gut bacteria.

Subject of Research: Sex differences in hedonic feeding and the effects of antibiotic-induced gut microbiome disruption in rats

Article Title: Sex differences in hedonic feeding and characterizing the effects of antibiotic-induced microbiome disruption

Article References: Sex differences in hedonic feeding and characterizing the effects of antibiotic-induced microbiome disruption. (n.d.). https://doi.org/10.1186/s13293-026-00970-1

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00970-1

Keywords: hedonic feeding, gut microbiome, sex differences, behavioral economics, obesity, antibiotics, short chain fatty acids, bile acids, operant conditioning, Sprague-Dawley rats, microbiome disruption, food reward